In This Article:
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value
TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases. The expanded agreement aims to deliver greater cost leadership and productivity enhancement for Gilead while seeking to extract greater value from the existing relationship. Leveraging machine learning and generative AI within an agentic framework, the work addresses multiple use cases across customer service, employee interactions, and business value management. Gilead is expected to enhance its efficiency through leveraging Cognizant's expertise in AI and advanced technology applications. By deploying these cutting-edge solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Over the last decade, Cognizant has helped support Gilead's global IT infrastructure, platforms, applications and advanced analytics, and leads initiatives designed to accelerate its digital transformation. Today's announcement builds on a collaboration aimed at creating capacity to allow Gilead to continue its focus and mission, aimed at discovering and delivering critical medicines for cancer, HIV and other diseases.
"Cognizant continues to provide critical expertise as we advance our technology journey," said Joydeep Ganguly, SVP & Head – Corporate Operations and Interim CIO at Gilead. "The expansion of this partnership is pivotal in accelerating our capabilities roadmap while driving a new level of cost leadership across our technology programs. This collaboration aims to bring innovative changes to Gilead's business, exploring new possibilities and enhancing our operations in novel ways."
Expanding on the company's partnership, Cognizant intends to leverage its Neuro AI generative AI platform to assist Gilead in accelerating value creation, enhancing IT and business processes, and improving operational efficiencies. This initiative aims to provide significant cost savings, which can be reinvested into Gilead's core life sciences business. As part of this expanded agreement, Cognizant also intends to transform the user experience of IT services with custom-built Gen AI solutions that allow Gilead to benefit from greater efficiency and user experience.